StrykerSYK
SYK
About: Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
Employees: 52,000
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 14 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
91% more first-time investments, than exits
New positions opened: 153 | Existing positions closed: 80
2% more funds holding
Funds holding: 1,948 [Q2] → 1,990 (+42) [Q3]
10% more repeat investments, than reductions
Existing positions increased: 780 | Existing positions reduced: 712
4% more capital invested
Capital invested by funds: $106B [Q2] → $110B (+$4.1B) [Q3]
9% less call options, than puts
Call options by funds: $586M | Put options by funds: $641M
1.61% less ownership
Funds ownership: 81.69% [Q2] → 80.07% (-1.61%) [Q3]
3% less funds holding in top 10
Funds holding in top 10: 77 [Q2] → 75 (-2) [Q3]
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$370
4%
downside
Avg. target
$415
8%
upside
High target
$450
17%
upside
14 analyst ratings
12 positive
86%
2 neutral
14%
0 negative
0%
RBC Capital Shagun Singh 46% 1-year accuracy 32 / 69 met price target | 11%upside $425 | Outperform Reiterated | 7 Jan 2025 |
Needham Mike Matson 52% 1-year accuracy 64 / 122 met price target | 15%upside $442 | Buy Reiterated | 7 Jan 2025 |
Truist Securities Richard Newitter 79% 1-year accuracy 33 / 42 met price target | 7%upside $409 | Hold Maintained | 18 Dec 2024 |
Citigroup Joanne Wuensch 60% 1-year accuracy 28 / 47 met price target | 17%upside $450 | Buy Maintained | 11 Dec 2024 |
Wells Fargo Larry Biegelsen 63% 1-year accuracy 29 / 46 met price target | 11%upside $427 | Overweight Maintained | 11 Dec 2024 |
Financial journalist opinion
Based on 10 articles about SYK published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Stryker commences tender offer for all outstanding shares of common stock of Inari Medical, Inc.
Portage, Michigan, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) today announced that it is commencing, through a wholly owned subsidiary, Eagle 1 Merger Sub, Inc., a cash tender offer to purchase all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80.00 per share in cash. The offer is being made pursuant to the previously announced merger agreement, dated as of January 6, 2025, among Stryker, Eagle 1 Merger Sub, Inc and Inari.
Positive
Zacks Investment Research
1 week ago
PAHC or SYK: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Neutral
Business Wire
1 week ago
INARI MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inari Medical, Inc. - NARI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inari Medical, Inc. (NasdaqGS: NARI) to Stryker (NYSE: SYK). Under the terms of the proposed transaction, shareholders of Inari will receive $80.00 in cash for each share of Inari that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the c.
Positive
Zacks Investment Research
1 week ago
Stryker Stock Falls Despite the Agreement to Acquire Inari Medical
SYK inks an agreement to acquire Inari Medical at a valuation of approximately $4.9 billion.
Positive
Benzinga
1 week ago
Stryker To Buy Inari Medical In $5 Billion Deal To Bolster Venous Thromboembolism Position
On Monday, Stryker Corporation SYK agreed to acquire Inari Medical Inc. NARI for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion.
Positive
Investors Business Daily
2 weeks ago
Inari Medical Catapults — Again — After Stryker Confirms $4.9 Billion Deal
Medical devices behemoth Stryker agreed to buy Inari Medical for $4.9 billion late Monday. Inari stock catapulted on the news.
Neutral
GlobeNewsWire
2 weeks ago
Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment
Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion. Inari, which was founded in 2011, will bring a leading peripheral vascular position in the fast-growing segment of venous thromboembolism (VTE) to Stryker. Inari's innovative product portfolio is highly complementary to Stryker's Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.
Positive
Reuters
2 weeks ago
Exclusive: Medical device maker Stryker nearing a deal to buy Inari Medical, sources say
Medical-device maker Stryker is in advanced talks to acquire Inari Medical , which makes devices that treat patients with venous diseases, people familiar with the matter told Reuters on Monday.
Positive
MarketBeat
2 weeks ago
3 Stocks Helping Bring AI to Healthcare
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Positive
Zacks Investment Research
3 weeks ago
5 MedTech Stocks That Are Poised to Beat the Market in 2025
Here, we discuss five stocks that are likely to generate better than the market, driven by strong demand for existing products and the addition of innovative new devices.
Charts implemented using Lightweight Charts™